Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and famitinib for third-line or later soft tissue sarcoma
ChiCTR2400095075Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab and famitinib in soft tissue sarcoma (STS) (3 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: 3-month progression-free survival rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
adebrelimabfamitinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2400095075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400095075.